Dr. Dong Xu: Meeting More Patient Needs in HIV Health Management

Dr. Dong Xu: Meeting More Patient Needs in HIV Health Management

2024.01.15
Implementation Science is a relatively new and increasingly recognized field of research. Its purpose is to translate the possibilities outlined in theory into practical applications in the real world, addressing the challenges of implementing validated intervention measures. At the 2023 APACC conference, Dr. Dong Hsu, from the School of Public Health Management and the Global Health Research Center, Southern Medical University, China, delivered an insightful presentation titled "Implementation of Clinical Practice Guidelines". In our interview, Dr. Dong Hsu further elaborated on the definition and research value of Implementation Science and shared his team's research findings in areas such as HIV screening and health management.
Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

2024.01.14
Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.
Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

2024.01.14
Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.
Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

2023.10.23
Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.
Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

2023.10.22
Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.
Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

2023.10.22
Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.
Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

2023.10.22
The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li's team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li 's team, based on the latest findings from a large cohort study, revealed that the hepatitis B surface antigen (HBsAg) clearance rate in HIV/HBV co-infected individuals who received long-term combination antiretroviral therapy (cART) could reach 8.1%. Furthermore, the research results unveiled that the main influencing factors for HBsAg clearance in HIV/HBV co-infected individuals included low baseline HBsAg levels, HBV genotype B, and a more than two-fold increase in ALT within six months of treatment.
Dr. Lang Bai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence

Dr. Lang Bai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence

2023.10.22
Editor's Note: Over the years, significant progress has been made in the prevention and treatment of HIV/AIDS and co-infections. Society has provided the best medications and professional knowledge to combat HIV infections, making substantial contributions to those affected. From June 8th to 10th, 2023, the Asia-Pacific AIDS and Co-Infections Conference (APACC 2023) was held in Singapore. In this issue, we are honored to invite Dr. Lang Bai, Deputy Director of the Infectious Diseases Center, West China Hospital, Sichuan University, China, to share with us the latest research on Talaromyces marneffei infection, a common fungal disease among AIDS patients and other immunocompromised individuals in Southeast Asia.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

2023.10.22
Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

2023.10.22
Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.